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BACKGROUND:The accuracy of prostate-specific antigen (PSA) testing in prostate cancer detection is constrained by low sensitivity and
specificity. Dysregulated expression of minichromosome maintenance (Mcm) 2–7 proteins is an early event in epithelial multistep
carcinogenesis and thus MCM proteins represent powerful cancer diagnostic markers. In this study we investigate Mcm5 as a urinary
biomarker for prostate cancer detection.
METHODS: Urine was obtained from 88 men with prostate cancer and from two control groups negative for malignancy. A strictly
normal cohort included 28 men with complete, normal investigations, no urinary calculi and serum PSA o2ngml
–1. An expanded
control cohort comprised 331 men with a benign final diagnosis, regardless of PSA level. Urine was collected before and after
prostate massage in the cancer patient cohort. An immunofluorometric assay was used to measure Mcm5 levels in urine sediments.
RESULTS: The Mcm5 test detected prostate cancer with 82% sensitivity (confidence interval (CI)¼ 72–89%) and with a specificity
ranging from 73 (CI¼68–78%) to 93% (CI¼76–99%). Prostate massage led to increased Mcm5 signals compared with pre-
massage samples (median 3440 (interquartile range (IQR) 2280 to 5220) vs 2360 (IQR o1800 to 4360); P¼0.009), and was
associated with significantly increased diagnostic sensitivity (82 vs 60%; P¼0.012).
CONCLUSIONS:Urinary Mcm5 detection seems to be a simple, accurate and noninvasive method for identifying patients with prostate
cancer. Large-scale prospective trials are now required to evaluate this test in diagnosis and screening.
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Prostate-specific antigen (PSA) testing for prostate cancer has
shifted the focus of diagnostic strategies from the evaluation
of symptomatic men to the screening of asymptomatic men
years before the disease is clinically evident. Indeed, PSA is used
for informal screening, case finding, diagnosis, prognosis,
staging, monitoring of treatment and identification of recurrence
(Oesterling, 1991). As a result, there has been an increase in the
incidence of prostate cancer and the disease is now treated at an
earlier stage (Hernandez and Thompson, 2004).
However, PSA testing is constrained by low sensitivity and
specificity, reflected by its low area under the receiver operating
characteristic (ROC) curve (AUC¼0.678) (Thompson et al, 2005).
Therefore, many men undergo potentially unnecessary diagnostic
prostate biopsies that are painful and associated with risks of
sepsis and bleeding. PSA testing inevitably leads to the over-
treatment of some men, as the biopsy pathology, clinical findings
and PSA level do not adequately predict prognosis. Indeed, it has
been shown that preventing one prostate cancer-related death
requires between 17 and 48 radical prostatectomies (Holmberg
et al, 2002; Schroder et al, 2009). Thus, more accurate, noninvasive
testing methods are needed to identify life-threatening but curable
disease.
The initiation of DNA replication represents a final and critical
step in growth control downstream of complex and redundant
oncogenic growth signalling pathways, and is therefore a poten-
tially attractive diagnostic and therapeutic target (Williams and
Stoeber, 2007). Minichromosome maintenance (Mcm) proteins
2–7, the core components of the DNA replication initiation
machinery, participate in the assembly of pre-replicative
complexes (pre-RCs) on chromatin in G1 phase of the cell cycle,
establishing competence for initiation of DNA synthesis in the
subsequent S phase (Machida et al, 2005; Remus and Diffley, 2009).
The six Mcm proteins (MCM) constitute the DNA replicative
helicase and are therefore essential for chromosomal duplication.
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sThey are expressed throughout all phases of the cell division cycle,
but are tightly downregulated in quiescent (G0), differentiated and
senescent out-of-cycle states, and thus represent novel biomarkers
of growth (Eward et al, 2004; Barkley et al, 2007; Williams and
Stoeber, 2007). We and others have shown in a number of
epithelial organ systems that MCMs become dysregulated and
overexpressed in hyperproliferative dysplastic (preinvasive) and
malignant states, resulting in exfoliation of MCM-positive tumour
cells (Williams et al, 1998; Going et al, 2002; Williams and Stoeber,
2007). Moreover, the detection of exfoliated MCM-positive tumour
cells in urine sediments, cervical Papanicolaou smears or
gastroendoscopic-derived samples can be used in the detection
of bladder, cervical, oesophageal, pancreatic and biliary tract
cancers (Williams et al, 1998, 2004; Freeman et al, 1999; Stoeber
et al, 2002; Ayaru et al, 2008).
We previously observed that Mcm5 is overexpressed in prostate
cancer and that raised Mcm5 protein levels are an independent
predictor of survival on multivariate analysis in patients treated
with radical surgery (Meng et al, 2001) or androgen deprivation
therapy and radiotherapy (Dudderidge et al, 2007). Moreover, we
showed that elevated MCM expression in prostate cancer is
coupled to arrested tumour differentiation and increased activa-
tion of the mitogen/extracellular-signal-regulated kinase kinase
5/extracellular signal-regulated kinase 5 (MEK/ERK5) pathway
(Dudderidge et al, 2007). In contrast to premalignant and malig-
nant states, MCMs are expressed at very low levels in benign
prostatic tissue, with o2% of basal cells in normal and hyper-
plastic glands showing Mcm2 expression (Meng et al, 2001;
Dudderidge et al, 2007). These findings suggest that Mcm 2–7
might be exploited as biomarkers for prostate cancer detection.
Interestingly, in a study of Mcm5 as a biomarker for bladder
cancer, 12 patients presenting with haematuria were identified with
a new diagnosis of prostate cancer. These men had higher Mcm5
levels in urine sediments than men without malignancy (Po0.001).
Notably, Mcm5 was undetectable in 70 patients with benign
prostatic hyperplasia (Stoeber et al, 2002). Taken together, these
studies raise the possibility that detection of elevated levels of
Mcm5 may allow identification of prostate cancer patients with
clinically significant tumours.
Urine, expressed prostatic secretions and semen could all
provide suitable diagnostic material for biomarker detection of
prostate cancer. Semen collection is awkward and not always
possible, and the low volume of prostatic secretions restricts their
use. The prostate cancer gene 3 (PCA3) test, a urinary diagnostic
test for prostate cancer, uses a first-catch urine sample collected
after a brief prostate massage (post-massage sample). The PCA3
assay identifies non-coding mRNA from the PCA3 gene that is
overexpressed in prostate cancer (Hessels and Schalken, 2009).
The biological significance of this gene is unknown. However it
seems to be a useful diagnostic tool with an AUC value for prostate
cancer detection of 0.68 (Chun et al, 2009). Thus post-massage
urine samples seem to be an effective target for prostate cancer
detection.
In this pilot study we test the hypothesis that Mcm5 levels are
increased in urine sediments from men with prostate cancer
compared with men with no evidence of bladder or prostate
cancer. We also measure the effect of prostate massage on
Mcm5 levels.
MATERIALS AND METHODS
Study subjects
Patients attending urology or oncology clinics were recruited from
Addenbrooke’s Hospital (Cambridge, UK) and Freeman Hospital
(Newcastle upon Tyne, UK). All patients gave written consent
before being recruited to the study. Ethical approval was granted
locally for each institution (Cambridge Local Research Ethics
Committee reference no. 00/236, Newcastle Local Research
Ethics Committee reference no. 02/161). All consecutive patients
with a known diagnosis of prostate cancer who attended during
the study period when researchers were present were recruited
and categorised into pre- and post-treatment groups. Patients
undergoing investigation for prostate cancer, and who subse-
quently had prostate cancer identified, were also recruited to the
prostate cancer cohort. Patients who refused or could not give
informed consent, who had undergone recent urological instru-
mentation or who had current/previous urothelial cancer were
excluded. Where possible, samples were obtained from patients
both before and after a brief prostate massage. Pre-massage
samples comprised a whole voided urine specimen. Those patients
who underwent prostate massage provided a second sample.
Prostate massage involved 5–10 strokes lateral to medial on
each prostatic lobe. Any prostatic secretions expressed per urethra
were combined with a further whole voided urine specimen.
Relevant clinical data, including serum PSA and urine NMP22
concentrations, Gleason grade and Gleason score, clinical stage,
imaging determined lymph node status and bone scan status,
were recorded prospectively from clinical notes and pathology
records.
Men comprising the control groups were recruited from
haematuria clinics and only later included in the control arm if
investigations met strict selection criteria intended to exclude
those with coexisting genitourinary tract malignancy. A stringently
selected control group was identified to only include men with
negative haematuria tests and with no past history of bladder or
prostate cancer. Men with PSA levels 42ngml
–1, NMP22 levels
47Uml
–1, abnormal or atypical urine cytology or incomplete
haematuria investigations were excluded. Men with urolithiasis
were also excluded because of the known effect of urothelial
trauma causing release of MCM proteins from the dividing transit
compartment of the epithelium (Stoeber et al, 2002; Williams and
Stoeber, 2007). A second, expanded control group was identified to
include all men with a benign final diagnosis and no past history of
cancer, regardless of PSA measurements, that is, including patients
for whom no PSA measurement was available. Patients with
urinary calculi, incomplete investigations (e.g., visible haematuria
but no contrast imaging study) and atypical cytology but with a
benign final clinical diagnosis were not excluded from this group.
To approximately age match the group with prostate cancer cases,
men o50 years old were excluded. Patients who refused or could
not give informed consent, who had undergone recent urological
instrumentation or who had current or previous urothelial cancer
were excluded. Urine was provided by men in these control groups
without previous prostate massage.
Processing of urine sediments
Urine sediments were obtained by centrifuging urine samples at
1500g for 7min at 41C. The pelleted material was resuspended
in storage buffer (phosphate-buffered saline (PBS), 5% bovine
serum albumin, 1 M sucrose and 0.02% NaN3) that contained
one complete EDTA-free protease inhibitor cocktail tablet
(Roche Diagnostics, Burgess Hill, UK) per 50ml of buffer. The
resuspended urine sediments were stored in liquid nitrogen within
2h of the urine samples being passed.
Preparation of standards for immunofluorometric
Mcm5 assay
HeLa S3 cells (ATCC CCL-2.2) were cultured as exponentially
growing monolayers in Dulbecco’s modified Eagle medium
(Invitrogen, Paisley, UK) supplemented with 10% fetal calf serum
(Invitrogen), 100Uml
–1 penicillin and 0.1mgml
–1 streptomycin
in a 371C humidified incubator in the presence of 5% CO2. HeLa
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scells were harvested after trypsinisation and diluted with storage
buffer to concentrations of 1500, 5000, 15000, 50000, and 150000
cells per well. The zero-cell standard consisted of 500ml of storage
buffer. The standards were stored in liquid nitrogen and later used
to generate a standard curve for Mcm5.
Processing of standards and clinical samples
Standards and clinical samples were thawed, and cells were
isolated by centrifugation at 1500g for 5min at 41C. The
supernatants were discarded, and cell pellets were washed three
times with 500ml of PBS. Cell pellets were resuspended in 250ml
(for those pellets with a volume approximately o200ml) or 500ml
(for those pellets with a volume approximately 4200ml) of
processing buffer (PBS, 0.4% sodium dodecyl sulphate and 0.02%
NaN3). Cell lysates were prepared by incubating the resuspended
samples at 951C for 45min. The DNA in each sample was sheared
by passing the lysates through a 21-gauge needle (Terumo Europe,
Leuven, Belgium), and nucleic acids were digested with DNase I
(20Uml
–1; Roche Diagnostics) and RNase A (1mgml
–1; Roche
Diagnostics) for 2h at 371C. The samples were centrifuged at
15000g for 10min to pellet the cell debris, the supernatants were
collected, and 50ml of each was directly used in the immuno-
fluorometric assay.
Immunofluorometric measurement of Mcm5 levels in
urine sediments
Monoclonal antibodies (MAbs) 12A7 and 4B4 raised against
His-tagged human Mcm5 were protein A-purified from hybridoma
supernatants as described (Stoeber et al, 2002). Monoclonal
antibody 4B4 was labelled with europium using a DELFIA
Eu-labelling kit (PerkinElmer, Turku, Finland) according to the
manufacturer’s instructions. The assay was standardised using
HeLa cells, and one fluorescence unit was defined as the signal
generated by the Mcm5 contents of one proliferating HeLa cell,
approximately 10
5 Mcm5 molecules (Kearsey and Labib, 1998).
DELFIA research reagents were obtained from PerkinElmer. All
other reagents were obtained from Sigma-Aldrich (Dorset, UK).
Multibuffer was prepared from 0.2 vol 5  DELFIA assay
buffer (PerkinElmer), 0.125 vol DELFIA TSH-Ultra assay buffer
(PerkinElmer) and 0.1 vol Tween 20 (Sigma-Aldrich). Immuno-
fluorometric measurements of Mcm5 levels were performed as
described (Stoeber et al, 2002). Standard curves were constructed
from fluorescence values generated by the blank and standard
wells, and the fluorescence values of the urine sediment samples
were calculated with the Multicalc Advanced Immunoassay Data
Management package (PerkinElmer). For immunofluorometric
measurement of Mcm5 levels, assay standards, control urine
sediment samples and urine sediments from prostate cancer
patients were run as duplicates and the mean of the duplicate
results reported. For acceptance of immunofluorometric measure-
ments in the assay, the following coefficients of variation were
required: CV o20% for results between 1500 and 5000 cells per
well standard curve points; CV o15% for results between 5000 and
15000 cells per well; and CV o10% for results of 415000 cells
per well.
Immunoassay performance
In our analysis of patient samples, we used 1800 cells per well as
the lower detection limit because the within-batch variation of the
assay for cell dilutions o1800 cells per well was 420%. Samples
that generated an immunofluorometric signal below that corre-
sponding to 1800 cells per well were reported as having o1800
cells per well.
Statistical analysis
The amplitude of the Mcm5 fluorescence signal for each patient
subgroup is presented as the median value with an associated
interquartile range (IQR). Test performance was evaluated by
calculating sensitivity and specificity using SPSS software, version
12.0.1 (SPSS, Chicago, IL, USA). An exact 95% confidence interval
(CI) for each proportion was derived assuming a binomial
distribution. Pre- and post-massage Mcm5 fluorescence signals
were compared using the Wilcoxon signed-rank test for paired
data. The difference in test performance for pre- and post-massage
samples was assessed by comparing each sensitivity figure using
McNemar’s test. The w
2 tests were used to compare the sensitivity
in different subgroups. All statistical tests were two tailed, and a
5% level was used to indicate statistical significance.
RESULTS
Prostate cancer cohort demographics
Clinical characteristics, including age, serum PSA level, stage,
grade distribution and treatment status for the cancer patient
cohort, are shown in Table 1. In all, 88 men with prostate
cancer were recruited with a median age of 72 years (IQR 66–77
years) and a median PSA concentration of 7.8ngml
–1 (IQR
3.8–23.7ngml
–1). The group was heterogeneous and included
patients at all stages in the diagnostic and treatment pathway. The
majority of patients were in clinical stage T1 (27%) and T2 (38%),
with lower proportions in T3 (22%) and T4 (3%). Of the 88 prostate
cancer patients, 39 were classified as ‘untreated’: 10 under active
surveillance, 21 with newly diagnosed cancer attending for treatment
decisions, 6 under investigation leading to a diagnosis of prostate
cancer and 2 initially diagnosed with benign disease whose repeat
biopsies showed prostate cancer. The median age of the untreated
group was 69 years (IQR 65–73 years). The remaining ‘treated’
group included 49 patients with previous or ongoing treatment for
prostate cancer, either androgen deprivation therapy, radiotherapy,
chemotherapy or a combination of these treatments (Table 1). The
median age of the treated patient cohort was 74 years (IQR 68–80
years), consistent with a more advanced stage of disease progres-
sion. Of the 49 treated patients, the majority were on luteinising
hormone-releasing hormone (LHRH) analogues alone (31%;
including patients awaiting radiotherapy), maximum androgen
blockade with LHRH analogues and anti-androgens (20%) or on
LHRH analogues after previous treatment with radiotherapy (24%).
Control cohort demographics
The clinical characteristics of both control cohorts are presented
in Table 2. For the strictly normal control group, 135 men with
PSA measurements and complete haematuria investigations
were initially recruited. Patients with a past history or investiga-
tions suggesting bladder or prostate cancer, PSA concentration
42ngml
–1, urine NMP22 concentration 47Uml
–1, urolithiasis
or visible haematuria and incomplete imaging were excluded,
leaving 28 men in the control cohort. This highly selected group
had a median age of 60 years (IQR 54–68 years) and a median
serum PSA concentration of 0.8ngml
–1 (IQR 0.5–1.3ngml
–1).
The presenting complaints were asymptomatic nonvisible haema-
turia (n¼8), symptomatic nonvisible haematuria (n¼11), pain-
less visible haematuria (n¼6), painful visible haematuria (n¼1)
and haematospermia (n¼2). Normal findings were identified in
11 men. Benign prostatic hyperplasia/obstruction was identified
in seven men, prostatitis in five men and urinary tract infection in
five men. Thus, although this group does not reflect a normal
population, it does reflect typical patients attending urology clinics
for investigation, and in whom malignancy can be excluded with
a high degree of certainty. For the expanded normal control group,
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s755 men were recruited in total. In all, 331 men were identified
from this group as potential controls after exclusion of men o50
years old with either a history of bladder or prostate cancer, cancer
identified during investigation or a positive NMP22 result
(47Uml
–1). The median age of this group was 68 years (IQR
59–75 years). For 55 men in this expanded cohort, PSA
measurements were available. The median value was 1.8ngml
–1
(IQR 0.8–4.95ngml
–1). The presenting complaints were asympto-
matic nonvisible haematuria (n¼75), symptomatic nonvisible
haematuria (n¼50), visible haematuria painless (n¼124), visible
haematuria painful (n¼46), haematospermia (n¼3) and un-
recorded/other (n¼33). Normal findings were identified in 154
men. Benign prostatic hyperplasia/obstruction was identified in
73, urinary calculi in 30, prostatitis in 7, urinary tract infection in
36, urethral stricture in 10, nephrological disease in 6 and other
benign diagnoses in 15 men. This larger group contained men with
no identifiable or previous cancer, but with the exception of a
small group tested with PSA, no specific tests to exclude prostate
cancer were made and thus a degree of contamination with occult
tumours is to be expected.
Urinary Mcm5 detection in prostate cancer patients and
normal controls
The cohort of 88 prostate cancer patients recruited for study
together provided 83 pre-massage and 60 post-massage urine
samples for Mcm5 immunofluorometric analysis. Table 3 and
Supplementary Figure 1 show the median Mcm5 signal for pre-
and post-massage urine samples, for the highest Mcm5 signal
group (i.e., Mcm5 signal for pre- or post-massage urine sample,
whatever the higher), and for both control groups. The median for
the highest Mcm5 signal group (3560 (IQR 2430–5575)) was
significantly higher compared with the strictly defined controls
(o1800 (IQR o1800 to o1800); Po0.001). Table 4 shows the
sensitivity of cancer detection for pre- and post-massage samples,
and for the highest Mcm5 signal group, as well as specificity values
for the two control groups. In addition, 2 2 tables based on the
highest recorded Mcm5 signal for all study participants and
Table 1 Clinical characteristics of prostate cancer patients
Characteristic n (%) or median (IQR)
All patients 88
Age, years 72 (66–77)
PSA, ngml
–1 7.8 (3.8–23.7)
a
Clinical T stage
T1 24 (27)
T2 33 (38)
T3 19 (22)
T4 3 (3)
Tx 9 (10)
Clinical M stage
M0 36 (41)
M1 18 (20)
Mx 34 (39)
Clinical N stage
N0 38 (43)
N1 0 (0)
Nx 50 (57)
Gleason score
p6 32 (36)
7 26 (30)
8 12 (14)
9 5 (6)
10 3 (3)
Unknown 10 (11)
Treatment status
Before diagnosis 2 (2)
Untreated 37 (42)
Treated 49 (56)
LHRH only 15 (31)
b
Antiandrogens alone 0 (0)
Radiotherapy alone 5 (10)
Chemotherapy alone 1 (2)
LHRH + antiandrogens 10 (20)
LHRH + radiotherapy 12 (24)
Radiotherapy + antiandrogens 1 (2)
Radiotherapy + chemotherapy 1 (2)
LHRH + radiotherapy + antiandrogens 3 (6)
LHRH + radiotherapy + chemotherapy 1 (2)
Abbreviations: LHRH¼luteinising hormone-releasing hormone; PSA¼prostate-
specific antigen; IQR¼interquartile range.
aN¼85.
bPercentage of treated group
(n¼49); rounded averages add up to o100%.
Table 2 Clinical characteristics of cancer-free control patients
n (%) or median (IQR)
Characteristic
Strictly
normal
Expanded
control
All patients 28 331
Age, years 60 (54–68) 68 (59–75)
PSA, ngml
–1 0.8 (0.5–1.3) 1.8 (0.8–4.95)
a
Initial referral
Asymptomatic nonvisible haematuria 8 (29) 75 (23)
Haematospermia 2 (7) 3 (1)
Indwelling catheter (haematuria) 0 (0) 1 (o1)
Symptomatic nonvisible haematuria 11 (39) 50 (15)
Visible haematuria, painful 1 (4) 46 (14)
Visible haematuria, painless 6 (21) 124 (37)
Unrecorded 0 (0) 32 (10)
b
Diagnosis on final evaluation
Normal 11 (39) 154 (47)
b
Benign prostatic hyperplasia/obstruction 7 (25) 73 (22)
Nephrological 0 (0) 6 (2)
Prostatitis 5 (18) 7 (2)
Urinary calculi 0 (0) 30 (9)
Urethral stricture 0 (0) 10 (3)
Urinary tract infection 5 (18) 36 (11)
Other 0 (0) 15 (5)
Abbreviations: PSA¼prostate-specific antigen; IQR¼interquartile range.
aN¼55,
includes strictly normal patients and those with PSA levels 42ngml
–1.
bRounded
percentages do not sum to 100%.
Table 3 Mcm5 signal for normal controls and prostate cancer patients
n Mcm5, median (IQR)
All cancer patients
Before massage 83 2680 (o1800–4720)
After massage 60 3415 (2140–5190)
Highest Mcm5 signal 88 3560 (2430–5575)
Cancer patients before and after massage
Before massage 55 2360 (o1800–4360)
After massage 55 3440 (2280–5220)
a
Normal controls
Strictly normal group – before massage 28 o1800 (o1800–o1800)
Expanded cohort – before massage 331 o1800 (o1800–1950)
Abbreviations: PSA¼prostate-specific antigen; IQR¼interquartile range;
Mcm¼minichromosome maintenance.
aCompared with before massage, P¼0.009
(Wilcoxon’s signed-rank test).
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spatients with pre-massage data only are shown in Supplementary
Tables 1 and 2, respectively. As maximum sensitivity was desired,
samples were scored as Mcm5 test positive if they generated a
signal above the lower threshold limit for detection of Mcm5
protein in the immunoassay (1800 cut point). Using the maximum
Mcm5 value obtained for each patient (i.e., either the pre- or
post-massage Mcm5 signal), the overall sensitivity was 82% (72 out
of 88; CI¼72–89%) and specificity was 93% (26 out of 28;
CI¼76–99%). The sensitivity using the pre-massage samples only
was 65% (54 out of 83; CI¼54–75%) and the sensitivity using the
post-massage samples only was 78% (47 out of 60; CI¼66–88%).
Of the 26 strictly normal control patients who tested negative,
7 were diagnosed with benign prostatic hyperplasia. In a previous
study we reported similar low Mcm5 signals for 70 men with
benign prostatic hyperplasia, indicating that the specificity of the
Mcm5 test is unaffected by this common condition (Stoeber et al,
2002). Interestingly, both of the strictly normal control patients
who had elevated Mcm5 signals and tested positive presented with
haematospermia. To consolidate our finding that Mcm5 is of
diagnostic utility in prostate cancer detection, further analysis
was performed using less stringent exclusion criteria to identify
an expanded control cohort. The median Mcm5 signal in this
group was o1800 (IQR o1800 to 1950; Table 3) and was still
significantly lower than the cancer group (Po0.001). Using this
expanded control cohort, high specificity was still observed at
73% (242 out of 331; CI¼68–78%; Table 4 and Supplementary
Figure 1). The false positives detected in this expanded control
group (Mcm5 signal 41800) included normals without identifiable
pathology (42 out of 154, 27%), urinary tract infection (10 out of
36, 28%) and urethral stricture (4 out of 10, 40%), benign prostatic
hyperplasia (17 out of 73, 23%), calculi (15 out of 30, 50%),
prostatitis (2 out of 7, 29%) and others (3 out of 15, 20%).
The effect of prostate massage on the Mcm5 signal and its effect
on diagnostic sensitivity were also studied. From the prostate cancer
cohort, 55 men provided both pre- and post-massage samples. As
shown in Table 3 and Supplementary Figure 1, prostate massage
led to a significant increase in median Mcm5 signal from 2360
(IQR o1800 to 4360) to 3440 (IQR 2280 to 5220; P¼0.009). The
increased amplitude of the Mcm5 signal after prostate massage was
associated with a significant increase in diagnostic sensitivity from
60 (CI¼46–73%) to 82% (CI¼69–91%; P¼0.012; Table 4).
To determine the relationship between Mcm5 signal and PSA
level, prostate cancer patients were grouped by PSA concen-
tration: o5, 5–15 and 415ngml
–1. All three groups showed
elevated Mcm5 signals and similarly high sensitivities (Table 5 and
Supplementary Figure 2). Notably, when considering the highest
Mcm5 signal per patient, prostate cancer patients with a low
PSA level (o5ngml
–1; n¼26) had a median Mcm5 signal
of 3170 (IQR 2152–5887) and associated sensitivity of 81%
(CI¼61–93%), equivalent to prostate cancer patients with
high PSA values (415ngml
–1; n¼30) who had a median Mcm5
signal of 4065 (IQR 2450–5337) and associated sensitivity of
83% (CI¼65–94%; P¼0.88).
To investigate the relationship between clinical characteristics
and Mcm5 signal, the cancer patient cohort was further sub-
classified according to clinical stage (T1, T2 and T3/4), Gleason
score (p6, 7 and 8–10), lymph node involvement and distant
metastasis. The Mcm5 signal and sensitivity of the test were not
influenced by any of these clinicopathological variables (Table 5,
Supplementary Table 3 and Supplementary Figures 3 and 4).
Surprisingly, the overall treatment status of patients did not seem
to have a major effect on the Mcm5 signal. When the sensitivities
for untreated (87% (CI¼73–96%)) and treated patients (78%
(CI¼63–88%)) were compared, no statistical difference was
observed between the two (P¼0.36; Supplementary Table 4).
However, considering only patients who provided a sample after
prostate massage, we noted a decrease in median Mcm5 signal
in those patients who underwent radiotherapy (2820 (IQR o1800
to 3960)) relative to those who did not undergo radiotherapy
(3870 (IQR 2550 to 5870); Supplementary Table 4). This decrease
in Mcm5 signal was associated with a significantly decreased
sensitivity (54% (CI¼25–81%) vs 87% (CI¼70–96%); P¼0.04).
Table 4 Sensitivity and specificity analysis of Mcm5 test performance in
normal controls and prostate cancer patients
n %( C I )
All cancer patients
Before massage 83 Sensitivity 65 (54–75)
After massage 60 Sensitivity 78 (66–88)
Highest Mcm5 signal 88 Sensitivity 82 (72–89)
Cancer patients before and after massage
Before massage 55 Sensitivity 60 (46–73)
After massage 55 Sensitivity 82 (69–91)
a
Normal controls
Strictly normal group – before massage 28 Specificity 93 (76–99)
Expanded cohort – before massage 331 Specificity 73 (68–78)
Abbreviations: CI¼confidence interval; Mcm¼minichromosome maintenance.
aCompared with before massage, P¼0.012 (McNemar’s test). Sensitivity and
specificity were determined using a cut point of 1800 for Mcm5 signal.
Table 5 Mcm5 signal test sensitivity in cancer patients categorized by PSA level, clinical stage and Gleason score
Pre-massage Post-massage Highest Mcm5 signal
n
Mcm5,
median (IQR)
Sensitivity
% (CI) P (n)* P (t)
w n
Mcm5,
median (IQR)
Sensitivity
% (CI) P (n) P (t) n
Mcm5,
median (IQR)
Sensitivity
% (CI) P (n) P (t)
PSA, ngml
–1
o5 25 2180 (o1800 to 4190) 56 (34–76) — — 20 3170 (1874 to 5587) 75 (51–91) — — 26 3170 (2152 to 5887) 81 (61–93) — —
5–15 26 2365 (o1800 to 3947) 62 (41–80) 0.77 0.21 23 3870 (2280 to 5160) 83 (61–95) 0.65 0.96 29 3870 (2250 to 5240) 79 (60–92) 0.95 0.80
415 29 3440 (o1800 to 5075) 72 (53–87) 0.24 — 16 3290 (1914 to5037) 75 (48–93) 1.00 — 30 4065 (2450 to 5337) 83 (65–94) 0.88 —
Clinical stage
T1 23 2460 (o1800 to 5000) 61 (39–80) — — 18 4485 (3210 to 7797) 94 (73–100) — — 24 4505 (3007 to 6900) 92 (73–99) — —
T2 30 2210 (o1800 to 3140) 60 (41–77) 0.98 0.70 28 2625 (o1800 to 4240) 68 (48–84) 0.08 0.06 33 2680 (2045 to 4445) 79 (61–91) 0.33 0.05
T3/4 21 3470 (o1800 to 5290) 67 (43–85) 0.75 — 9 2560 (o1800 to 4300) 67 (30–93) 0.22 - 22 3500 (o1800 to 5330) 68 (45–86) 0.10 —
Gleason score
p6 32 2310 (o1800 to 3420) 62 (44–79) — — 24 3800 (2887 to5707) 87 (68–97) — — 32 3545 (2715 to 5707) 91 (75–98) — —
7 22 2125 (o1800 to 3580) 55 (32–76) 0.58 0.77 19 3660 (o1800 to 5160) 74 (49–91) 0.37 0.05 26 3375 (o1800 to 4830) 69 (48–86) 0.10 0.12
8–10 19 3530 (o1800 to 5660) 68 (43–87) 0.70 — 12 2340 (o1800 to 3212) 58 (28–85) 0.13 — 20 3255 (1942 to 5552) 75 (51–91) 0.27 —
Abbreviations: CI¼confidence interval; Mcm¼minichromosome maintenance; IQR¼interquartile range; PSA¼prostate-specific antigen. *P-value for sensitivity, vs base
category (w
2 test).
wP-value for trend across category.
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sDISCUSSION
There is an urgent need for more accurate, noninvasive diagnostic
testing for prostate cancer. Although serum PSA-based screening
has been shown to reduce prostate cancer mortality by 20%, there
is a high risk of diagnosis of clinically insignificant tumours
(Schroder et al, 2009). Recent data from the European Randomized
Study of Screening for Prostate Cancer (ERSPC) showed that 1410
men would require screening and an additional 48 cancers treated
to prevent one death from prostate cancer (Schroder et al, 2009).
Moreover, the high PSA false-positive rate observed in this study
(76%) shows the high number of prostate biopsies that might be
avoided if a more accurate diagnostic test was available. Crucially,
the disproportionate number of cancers that must be treated to
prevent one death underlines the inadequate understanding of
prostate cancer biology. Future diagnostic methods must not only
reduce unnecessary prostate biopsies, but also provide prognostic
information to aid treatment decisions. Moreover, the ideal
diagnostic marker would preferentially identify clinically signi-
ficant prostate cancers with a high risk of progression.
In this study we have identified Mcm5 as a potentially important
biomarker for prostate cancer detection. Principally, we have shown
that Mcm5 levels are elevated in the urine cell sediments of prostate
cancer patients when compared with patients without malignancy.
Only two patients had an elevated Mcm5 signal in the strictly normal
control group. Interestingly, both patients presented with haematos-
permia and normal clinical investigations. This symptom is often
because of prostatic calculi causing trauma to the prostatic ducts
(Kumar et al, 2006). This would potentially expose the normal MCM-
expressing proliferative compartment to the lumen of these ducts, and
may thus explain the two false-positive results. Similarly, patients in the
expanded haematuria control group diagnosed with bladder calculi also
showed elevated Mcm5 signals. This confirms our previous findings
that calculi in the genitourinary tract generate elevated Mcm5 signals in
urine cell sediments (Stoeber et al, 2002). Importantly, the 73 patients
with BPH included in this study did not show elevated Mcm5 signals
compared with those controls without pathology. Similarly,
70 patients with BPH analysed as part of a previous Mcm5 bladder
cancer trial did not show elevated Mcm5 levels (Stoeber et al, 2002).
This is consistent with the fact that MCM expression levels in
hyperplastic glands are very low (o2% of basal cells), similar to those
observed in normal prostatic tissue (Meng et al, 2001; Dudderidge et al,
2007). Notably, prostatitis was associated with an elevated Mcm5 signal.
A reduction in specificity of the Mcm5 test, from 93 to 73%, was
observed when using the expanded control cohort. Although this
measure of specificity was derived from a much larger population,
the PSA values were unknown for the majority. This expanded
control cohort is therefore likely to include occult prostate cancers.
Indeed, if one considers that the prevalence of prostate cancer in
the Prostate Cancer Prevention Trial was 20.7% in the 55- to
59-year-old group (in a group originally comprising patients with
normal digital rectal examination and PSA o3ngml
–1; Thompson
et al, 2003), one might expect a significant number of occult
prostate cancers to be included within our expanded control
population. Interestingly, the Mcm5 false-positive rate in the
normal population without detectable pathology was 27%. It will
therefore be of interest in future studies to determine what
percentage of these cases might represent occult prostate cancers.
In the context of prostate cancer detection, we have also
established the importance of prostate massage in the preparation
of urine samples for Mcm5 testing. This brief procedure is well
tolerated by patients in the urology clinic and is an integral part of
their clinical assessment. Little variation from standard examina-
tion is required to optimise sample quality. We have shown that
massage not only increased Mcm5 signals in urine sediments, but
it also led to significantly increased diagnostic sensitivity. These
findings require verification in a larger study with all patients
undergoing pre- and post-massage testing.
It is interesting to note that there was no major reduction in Mcm5
signals after medical therapeutic intervention. We have previously
shown in normal tissues and tumours that cells arrested ‘in cycle’ can
maintain MCM protein expression, designated as ‘licensed’ cells with
proliferative potential (Stoeber et al, 2001; Dudderidge et al, 2005;
Williams and Stoeber, 2007). Persistence of elevated Mcm5 signals in
the urine sediments of treated patients suggests that there has been no
significant reduction in tumour cell volume, and this may contribute
to relapse after such medical therapeutic interventions. Disease
progression could be triggered by the overriding of DNA damage cell
cycle checkpoints or, alternatively, through the establishment of
growth-independent (autonomous) cancer cell cycles.
Prostate-specific antigen is primarily an organ-specific marker and
its elevation in prostate cancer is because of the leakage of a
physiological protein into the blood, resulting from the disruption of
the basement membrane (Lilja et al, 2008). Thus, PSA is not an ideal
tumour marker as it is also elevated in other prostatic diseases that
cause increased permeability of the basement membrane, including
BPH and prostatitis (Lilja et al, 2008). In contrast, Mcm5 detection
can be regarded as a cancer-specific test. Therefore, the combination
of a cancer-specific test in Mcm5 with a prostate-specific test in PSA
may provide an improved algorithm for prostate cancer detection.
Although this pilot study has identified Mcm5 as a new
biomarker for prostate cancer detection, it is not yet clear whether
the test will be able to specifically identify clinically significant
cancers. Comparable sensitivities and Mcm5 signals were observed
between low-grade, low-stage and high-grade, advanced-stage
tumours. However, this is a heterogeneous patient cohort, in
which many patients have undergone therapeutic intervention.
Trials on a conventional diagnostic untreated patient cohort will
be required to address this question. Future studies should also
evaluate the combination and comparison of serum PSA, urinary
PCA3 and Mcm5, and assess the use of a combined predictive
biomarker algorithm that may allow identification of patients
in whom prostate biopsy can be safely avoided.
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